Ketamina, da anestesia ao uso abusivo
artigo de revisão
DOI:
https://doi.org/10.34024/rnc.2010.v18.8486Palavras-chave:
Ketamina, Anestesia, Analgesia, Depressão, Drogas de Abuso.Resumo
Objetivo. Realizar uma revisão bibliográfica sobre a ketamina, enfocando aspectos químicos e farmacocinéticos, seus mecanismos de ação, efeitos farmacológicos, usos terapêuticos, bem como aborda o uso da ketamina como droga de abuso. Ketamina. Método. Estudo de revisão bibliográfica através das bases de dados Pubmed, SciELO, Lilacs e Medline, na qual foram selecionados estudos clássicos e recentes relevantes para a discussão do tema abordado. Resultados. Após análise dos artigos selecionados, conclui-se que a ketamina apresenta perspectivas promissoras. Alguns estudos demonstraram propriedades analgésicas em relação à dor pós-operatória e outros revelaram uma ação antidepressiva rápida. Além disto, a ketamina também apresentou efeitos neuroprotetores em vários estudos animais. Embora a ketamina seja um campo promissor, essas ações precisam ser melhor investigadas. Atualmente, observou-se que o seu uso não se restringe apenas à prática clínica ou pesquisa, sendo frequentemente utilizada como droga de abuso pelos jovens em festas como um potente alucinógeno. Conclusão. Pesquisas sobre o uso recreacional da ketamina também são necessárias, especialmente no Brasil, assim como dados que mostrem a morbidade e mortalidade pelo uso desta substância como droga de abuso.
Downloads
Métricas
Referências
Focchi GRA. Dependência de drogas: uma abordagem para leigos. Psychiatr on line Braz 2004;9:1-15.
Pratta EMMS, Santos MA. Levantamento dos motivos e dos responsáveis pelo primeiro contato de adolescentes do ensino médio com substâncias psicoativas. SMAD. Rev Elet Saúde Mental Álcool Drog 2006;2:1-17.
Laranjeira R, Surjan J. Conceitos básicos e diagnóstico. J Bras Depend Quím 2001;2:2-6.
Smith KM, Larive LL, Romanelli F. Club drugs: methylenodioxymethamphetamine, flunitrazepam, ketamine, hydrocloride and y-hydroxybutyrate. Am J Health Syst Pharm 2002;59:1067-76.
Garcia JBS. Cetamina uma nova leitura. Prática Hospitalar. 2007;53:214-6.
Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000;47:351-4.
Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, et al. A randomized trial of an N-Methyl-D-Aspartate antagonist in treatment-resistant major depression. Arch. Gen. Psychiatry. 2006;63:856-64.
Umbricht D, Schmid L, Koller R, Vollenweider FX, Hell D, Javitt DC. Ketamine-induced defficts in auditory and visual cortext-dependent processing in healthy volunteers: implications for models of cognitive deficits in schizophrenia. Arch. Gen. Psychiatr 2000;57:1139-47.
Duncan EJ, Madonick SH, Parwani A, Angrist B, Rajan R, Chakravorty S, et al. Clinical and sensorimotor gating effects of ketamine in normals. Neuropsychopharmacol 2001;25:72-83.
Glabe RS. Acute toxic effects of club drugs. J Psych Drugs 2004;36:303-13.
Oliveira CMB, Sakata RK, Issy AM, Garcia JBS. Cetamina e Analgesia Preemptiva. Rev Bras Anestesiol. 2004;54: 739-52.
Luft A, Mendes FF. S(+) Cetamina em Baixas Doses: Atualização. Rev Bras Anestesiol. 2005;55:460- 9.
Kohrs R, Durieux ME. Ketamine: Teaching an Old Drug New Tricks. Anesth Analg. 1998; 87: 1186-93.
Hemelrijck JV, White P. Nonopioid Intravenous Anesthesia. In: Barash PG, Cullen BF, Stoelting RK (eds.). Clinical Anesthesia. 3th ed. Philadelphia: Lippincott-Raven, 1997, p.312-27.
Plenninger EG, Durieux ME, Himmelseher S. Cognitive impairment after small-dose ketamine isomers in comparison to equianalgesic racemic ketamine in human volunteers. Anesthesiol 2002;96:357-66.
Jaksch W, Lang S, Reichhalter R, Raab G, Dann K, Fitzal S. Perioperativesmall-dose S(+)-ketamine has no incremental beneficial effects on postoperative pain when standard-practice opioid infusions are used. Anesth Analg. 2002;94:981-6.
Lauretti GR, Lima ICPR, Buscatti RY, Reis MP. Avaliação clínica dos efeitos hemodinâmicos, analgésicos, psicodélicos e de bloqueio neuromuscular da cetamina racêmica e de seu S(+) isômero. Rev Bras Anestesiol. 2000;50:357-62.
Duval neto GF. Anestésicos Venosos. In: Manica J (eds.). Anestesiologia Princípios e Técnicas. 3th ed. Porto Alegre: Artmed, 2004, p.560-97.
Bannerman DM, Good MA, Butcher SP, Ramsay M, Morris RG. Distinct components of spatial learning reveated by prior training and NMDA receptor blockade. Nature. 1995;378:182-6.
Rang HP, Dale MM, Ritter JM. Farmacologia. 6ª. ed. Rio de Janeiro: Elsevier, 2007, 920p.
Gonzales JM, Loeb AL, Reichard PS, Irvine S. Ketamine inhibits glutamate-, N-methyl-D-aspartate- and quisqualate-stimulated cGMP production in cultured cerebral neurons. Anesthesiology. 1995;82:205-13.
Gordh T, Karlsten R, Kristensen J. Intervention with spinal NMDA, adenosine and NO systems for pain modulation. Ann Med. 1995;27:229-34.
Hustveit O, Maurset A, Oye I. Interaction of the chira1 forms of ketamine with opioid, phencyclidine, and muscarinic receptors. Pharmacol Toxicol. 1995;77:355-9.
Raeder JC, Stenseth LB. Ketamine: a new look at an old drug. Curr opin Anesthesiology. 2000;13:463-8.
Smith DJ, Bouchal RL, deSanctis CA, Monroe PJ, Amedro JB, Perrotti JM, et al. Properties of the interaction between ketamine and opiate binding sites in vivo and in vitro. Neuropharmacology. 1982;26:1253-60.
Vasconcelos SMM, Andrade MM, Soares PM, Chaves BG, Patrocínio MCA, Sousa FCF, et al. Cetamina: aspectos gerais e relação com a esquizofrenia. Rev Psiq Clín 2005;32:10-6.
Martin DC, Watkins CA, Adams RJ, Nason LA. Anesthetic effects on 5-hydroxytryptamine uptake by rat brain synaptosomes. Brain Res. 1988;455:360-5.
Crisp T, Perrotti JM, Smith DL, Stafinsky JL, Smith DJ. The local monoaminergic dependency of spinal ketamine. Eur J Pharmacol. 1991;194:167-72.
Tonelli DG, Andreatini R. Antagonistas 5-HT3: uma nova classe de ansiolíticos? O exemplo do ondansetron. Rev Psiq Clín 2000;27:272-9.
Fisher K, Coderre TJ, Hagen NA. Targeting the N-methyl-D-Aspartate receptor for chronic pain management preclinical animal studies recent clinical experience and future research directions. J. Pain Symptom Manage. 2000;20:358-73.
Craven R. Ketamine. Anaesthesia. 2007;62:48-53.
WHO, Expert Committee on Drug Dependence, thirty-four report. Geneva. 2006
Green SM, Li J. Ketamine in adults: what emergency physicians need to know about selection and emergence reactions. Acad Emerg Med. 2000;7:278–81.
Luna SPL, Nogueira CS, Cruz ML, Massone F, Castro GB. Romifidine or xylazine combined with ketamine in dogs premedicated with methotrimeprazine. Brazilian Journal of Veterinary Research and Animal Science. 2000; 37:93-8.
Fraga AO, Malbouisson LMS, Prist R, Silva MR, Auler Júnior JOC. Indução anestésica após o tratamento do choque hemorrágico: Estudo experimental comparando a ketamina e o etomidato. Rev Bras Anestesiologia. 2006;56:377-90.
Thurmon JC, Tranquilli, WJ, Benson, GJ. Preanesthetics and anesthetic adjuncts.In: Thurmon JC, Tranquilli, WJ, Benson, GJ. Lumb & Jones veterinary anesthesia. 3th ed. Baltimore: Willians & Wilkins, 1996, p.183-209.
Hatschbach E, Massone F, Santos GJG, Beier SL. Parametria da associação do midazolam ou diazepam em cães pré-tratados pela atropina e tratados pela dexmedetomidina e quetamina. Cienc Rural. 2006;36:536-43.
Guedes AGP, Natalini CC. Anestesia em eqüinos com síndrome cólicaanálise de 48 casos e revisão de literatura. Cienc Rural. 2002;32:535-42.
Schulte H, Sollevi A, Segerdahl M . The synergistic effect of combined treatment with systemic ketamine and morphine on experimentally induced windup-like pain in humans. Anesth Analg. 2004;98:1574-80.
Pekoe GM, Smith DJ. The involvement of opiate and monoaminergic neuronal systems in the analgesia effects of ketamine. Pain. 1982;12:57-73.
Lodge D, Johnson KM. Noncompetitive excitatory amino acid antagonists. Trends Pharmacol Sci. 1990;11:81-6.
Argiriadou H, Himmelseher S, Papagiannopoulou P, Georgiou M, Kanakoudis F, Giala M, et al. Improvement of pain treatment after major abdominal surgery by intravenous S(+)-ketamine. Anesth Analg. 2004;98:1413-8.
Xie H, Wang X, Liu G, Wang G. Analgesic effects and pharmcokinetics of a low doses of ketamine preoperatively administered epidurally or intravenously. Clin J Pain. 2003;19:317-22.
Kararmaz A, Kaya S, Karaman H, Turhanoglu S, Ozyilmaz MA. Intraoperative intravenous ketamine in combination with epidural analgesia: postoperative surgery after renal sugery. Anesth Analg. 2003;97:1092-6.
Aida S, Yamakura T, Baba H, Taga K, Fukuda S, Shimoji K. Preemptive analgesia by intravenouslow-dose ketamine and epidural morphine in gastrectomy: a randomized double-blind study. Anesthesiology. 2000;92: 1624-30.
Elhakim M, Khalafallah Z, El-Fattah HA, Farouk S, Khattab A. Ketamine reduces swallowing-evoked pain after paediatric tonsillectomy. Acta Anaesthesiol Scand. 2003;47:604-9.
Haller G, Waeber JL, Infante NK, Clergue F. Ketamine combined with morphine for the management of pain in an opioid addict. Anesthesiology. 2002;96:1265-6.
- Friedberg BL. Propofol ketamine anesthesia for cosmetic surgery in the office suite. Int Anesthesiol Clin. 2003;41:39-50.
Nagasaka H, Nakamura S, Mizumoto Y, Sato I. Effects of ketamine on formalin-induced activity in the spinal dorsal horn of spinal cord-transected cats: differences in response to intravenous ketamine administered before and after formalin. Acta Anaesthesiol Scand. 2000;44:953-8.
Burton AW, Lee DH, Saab C, Chung JM. Preemptive intrathecal ketamine injection produces a long-lasting decrease in neuropathic pain behaviors in a rat model. Reg Anesth Pain Med. 1999;24:208-13.
Garcia LS, Comim CM, Valvassori SS, Réus GZ, Barbosa LM, Andreazza AC, et al. Acute administration of ketamine induces antidepressant-like effects in the forced swimming test and increases BDNF levels in the rat hippocampus. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32:140–4.
Crown WH, Finkelstein S, Berndt ER, Ling D, Poret AW, Rush AJ, et al. The impact of treatment-resistant depression on health care utilization and costs. J Clin Psychiatry. 2002;63:963–71.
Jick H, Kaye JA, Jick SS. Antidepressants and the risk of suicidal behaviors. JAMA. 2004;292:338-43.
Javitt DC. Glutamate as a therapeutic target in psychiatric disorders. Mol Psychiatry. 2004;9:984–97.
Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry. 1994;51:199-214.
Lewin GR, Barde YA. Physiology of the neurotrophins. Annu Rev Neurosci. 1996;19:289-317.
Karege F, Perret G, Bondolfi G, Schwald M, Bertschy G, Aubry JM et al. Decreased serum brain-derived neurotrophic factor levels in major depressed patients. Psychiatry Res. 2002;109:143-8.
Siuciak JA, Lewis DR, Wiegand SJ, Lindsay RM. Antidepressant-like effect of brain-derived neurotrophic factor (BDNF). Pharmacol Biochem Behav. 1997;56:131–7.
Nibuya M, Nestler EJ, Duman RS. Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus. J Neurosci. 1996;16:2365–72.
De Foubert G, Carney SL, Robinson CS, Destexhe EJ, Tomlinson R, Hicks CA, et al. Fluoxetine-induced change in rat brain expression of brain-derived neurotrophic factor varies depending on length of treatment. Neuroscience. 2004;128:597-604.
Hoffman WE, Pelligrino D, Werner C, Kochs E, Albrecht RF, Schulte am Esch J. Ketamine decreases plasma catecholamines and improves neurologic outcome from incomplete cerebral ischemia in rats. Anesthesiology.1992;76:755-62.
Shapira Y, Lam AM, Eng CC, Laohaprasit V, Michel M. Therapeutic time window and dose response of the beneficial effects of ketamine in experimental head injury. Stroke. 1994;25:1637-43.
Himmelseher S, Auchter M, Pfenninger E, Georgieff M. S(+)- ketamine prevents loss of mitochondrial transmembrane potential, increases glucose uptake and induces GAP-43 and MAP-2 expression in hippocampal neurons after giutamate exposure. Anesthesiology. 1996;85:7-11.
Himmelseher S, Pfenninger E, Georgieff M. The effects of ketamineisomers on neuronal injury and regeneration in rat hippocampal neurons. Anesth Analg. 1996;83:505-12.
Marcoux FW. Glutamate mediated excitotoxicity and experimental stroke. In: Kempski O. Glutamate-transmitter and toxin. Munich: Zuckschwedt, 1993, p.76-85.
Church J, Zeman S. Ketamine promotes hippocampal CA1 pyramidal neuron loss after a short-duration ischemic insult in rats. Neurosci Lett. 1991; 123: 65-8.
Jantzen JP. Cerebral neuroprotection and ketamine. Anaesthesist. 1994;43:41-7.
Arditti J, Spadari M, de Haro L, Brun A, Bourdon JH, Valli M. Ketamine - Dreams and realities. Acta Clinica Belgica. 2002;57:31-3.
Siegel RK. Phencyclidine and ketamine intoxication: a study of four populations of recreational users. NIDA Res Monogr. 1978;21:119-47.
Jansen KL. Non-medical use of ketamine. BMJ. 1993;306:601-2.
Aguaviva JJ, Cuartero R, Martínez JL, Redondo LC, Río T, Foncillas B. Drogas de diseño: un Nuevo paciente crítico. Manejo de las intoxicaciones por drogas consumidas en macrofiestas. Salud Rural. 2003;20:1-9.
Dillon P, Copeland J, Jansen K. Patterns of use and harms associated with non-medical ketamine use. Drug Alcohol Depend. 2003;69:23–8.
Jansen KL, Darracot-Cankovic R. The nonmedical use of ketamine, part two: A review of problem use and dependence. J Psychoactive Drugs. 2001;33:151–8.
Freese TE, Miotto K, Reback CJ. The effects and consequences of selected club drugs. J Subst Abuse Treat. 2002;23:151-6.
Copeland J, Dillon P. The health and psycho-social consequences of ketamine use. Int J of Drug Policy. 2005;16: 122-31.
Lankenau SE, Sanders B, Bloom JJ, Hathazi D, Alarcon E, Tortu S, et al. First injection of ketamine among young injection drug users (IDUs) in three U.S. cities. Drug and Alcohol Dependence. 2007;87:183–93.
Yen CF, Hsu SY, Cheng CP. Polysubstance use and its correlates in adolescent ecstasy users in Taiwan. Addictive Behaviors. 2007;32:2286–91.
Robinson TE, Berridge KC. Addiction. Annu Rev Psychol. 2003;54:25–53.
Trujillo KA, Zamora JJ, Warmoth KP. Increased Response to Ketamine Following Treatment at Long Intervals: Implications for Intermittent Use. J.Biopsych. 2008;63:178-83.
Keilhoff G, Becker A, Grecksch G, Wolf G, Bernstein HG. Repeated application of ketamine to rats induces changes in the hippocampal expression of parvalbumin, neuronal nitric oxide synthase and cFOS similar to those found in human schizophrenia. Neuroscience. 2004;126:591-8.
Zacny JP, Galinkin JL. Psychotropic drugs used in anesthesia. Practice, abuse, liability and epidemiology of abuse. Anesthesiology. 1999;90:269-88.
Dotson JW, Ackerman DL, West LJ. Ketamine abuse. J Drug Issues. 1995;25:751-7.
Hayase T, Yamamoto Y, Yamamoto K. Behavioral effects of ketamine and toxic interactions with psychostimulants. BMC Neurosci. 2006;7:1-10.
Verma A, Moghaddam B. NMDA receptor antagonist impair prefrontal cortex function as assessed via spatial delayed alternation performance in rats: Modulation by dopamine. J. Neurosci. 1996;16:373-9.
O’Donnell P, Grace A.A. Phencyclidine interferes with hipocampal gating of nucleus accumbens neuronal activity in vivo. Neuroscience. 1998;87:823-30.
Oranje B, van Berckel BN, Kemner C, van Ree JM, Kahn RS, Verbaten MN. The Effects of a Sub-Anaesthetic Dose of Ketamine on Human Selective Attention. Neuropsychopharmacology. 2000;22:293-302.
Adler CM, Malhotra AK, Elman I, Goldberg T, Egan M, Pickar D, et al. Comparison of ketamine – induced thought disorder in healthy volunteers and thought disorder in schizophrenia. Amer J Psychiat. 1999;156:1646-9.
Uhlhaas PJ, Millard I, Muetzelfeldt L, Curran HV, Morgan CJA. Perceptual organization in ketamine users: preliminary evidence of deficits on night of drug use but not 3 days later. J of Psychopharmacology. 2007;21:347–52.
Chu PS, Kwok SC, Lam KM, Chu TY, Chan SW, Man CW, et al. ‘Street ketamine’–associated bladder dysfunction: a report of ten cases. Hong Kong Med J. 2007;13:311-3.
Krupitsky EM, Burakov AM, Dunaevsky IV, Romanova TN, Slavina TY, Grinenko AY. Single versus repeated sessions of ketamine-assisted psychotherapy for people with heroin dependence. J Psychoactive Drugs. 2007;39: 13-9.
Krupitsky EM, Grinenko AY. Ketamine psychedelic therapy (KPT): a review of the results of ten years of research. J Psychoactive Drugs. 1997;29:165-83.
Downloads
Publicado
Como Citar
Edição
Seção
Publicado: 2010-06-30
Português
English
Español
